Member Info for RichKen

Lionel, you have done a sterling job and I have fully recommended your posts.

The current market cap and share price have no relationship to the real value potential profits and growth that are coming here.

Adding at these levels has soo much upside as a medium to long term investment. How long we will stay this low remains the question. But, when we do rise it will be fast.

Have a great day, and please stay safe all.

Cheers Rich

The only time you might see an additional cash raise is through a NASDAQ listing. Although, any did will be bought into very quickly given by then there will be multiple progress. Blautix is a potentially huge step forward for IBS treatment and the number of people suffering with IBS is clearly huge. The number of times GP's relate any issue with poor tummy response to IBS means that a treatment which can be trusted will be a massive comfort to sufferers.
The company has indicated the market for Blautix is around $3billion per year from global data as made clear in their presentation in August. So when this news comes you can see why the SP should see a huge lift!

Bought another £10K this morning, well why not! 161 is cheap compared to 350 to 400!

Cheers, Rich

Great blue start to the day! This is going up and up!
Great!

Live Biotherapeutics are a paradigm shift in medicine, a whole new class of drug much like the emergence of biologics and gene therapies. It is important to emphasise that Live Biotherapeutics are not a distant goal or immature concept, they are here and now, delivering game-changing clinical data and changing patients’ lives.

4D pharma is leading this rapidly emerging field, driven by its ‘function-first’ ethos and unparalleled platform technology, MicroRx. The platform has to date generated four unique clinical-stage Live Biotherapeutic drug candidates across a range of therapeutic areas, and a suite of pre-clinical programmes in new diseases. 4D is pushing the boundaries of the field, taking the microbiome beyond the gut in fields like oncology and neuroscience.

4D is best positioned to deliver on the promise of Live Biotherapeutics as the only truly end-to-end player in this exciting field. 4D pharma’s in-house capabilities cover the drug development spectrum, from discovery through manufacturing, IP protection, regulatory and clinical development.

Together these factors clearly demonstrate there is huge near- and long-term upside in 4D pharma, both from our development candidates currently in the clinic in major diseases with significant unmet need, but also in the MicroRx platform that drives us and our collaborations.
By Duncan Peyton

Looking forward to a great week ahead!

Cheers Rich

Totally undervalued! Having spent the afternoon watching presentations on 4d. They are going to be huge. Add in a dual listing on the NASDAQ and you have ingredients of a new 2020’s bio pharmaceutical mega company.
Cheers Rich

Hants, I will be topping up till we make £20 plus.
Cheers Rich

I am thinking a BAMS RNS is inbound.

Sorry folks not been catching up much on the Avacta board, but I am sure we will have a very strong week ahead, with a substantial bounce tomorrow.

Cheers Rich

If you are looking to understand where this company is heading you should watch this interview with the CEO.

https://youtu.be/DGHdLbuWdkc

This investment here is not a one day and out it should be a seen as a long term investment. If you buy and hold and go with the results as they come with success then you should see a very strong return.

It is very unlikely to pull back given the expectation of huge news.

If you wanter to learn more spend some time reading and watching the information on the website -https://www.4dpharmaplc.com/en

The presentations here will give a huge insight. https://www.4dpharmaplc.com/en/investors/reports-presentations

Just looking at IBS which effects millions of people around the world, having a successful treatment will be life changing and 4d Pharma look to have a ultra safe solution. That is hugely valuable.

Hope you enjoy your research.

Cheers, Rich

Bought out was the exact word meant, sorry for the typo.

Cheers Rich

Boombaby, You will find historically on substantial news a share price will jump dramatically. It is often called a spike. However depending on the news it can fall back quickly to level somewhere between the top of the spike and the price before the opening. The hard part is deciding what the spike will hit! Often on an RNS the market makers open the share price 5 to 10% higher. But then you can't trade manually. One way is to decide a number you want the share price to hit set a limit sell and the number of shares and when that number is reached as a sell price the sell goes through. You can then watch a wait and see if the share price drops back and then buy back in after a drop. This is a method professional traders use as well as long term holders to increase their holdings. 4d Pharma is a tough one to predict as the news this time could be so huge the share price could increase by 50%, 100% or even 200%. These things happen.
Nobody can advise you of what to do or what numbers to set, but this is a common route used to help people increase there holding. Use Limit sells and Limit buys. They are your friend. it stops you buying to high and selling after everyone else as sold and the share price has dropped back.

Today I have added another £20K here, and gained a few extra shares buy selling at close to the top of the share price today and buying close to the bottom. It works.

Oh and yes I am extremely positive we will see very strong growth over the next few weeks and long term we will see this companies valuation massively higher than it is today. Think £10 to £20, if they don't get caught out!

I will add a few more details when I get time over the weekend to help give a simplistic overview if people are interested.

Cheers, Rich

Have a great weekend!

Good morning all,
Yesterday I added another £20k here on full expectation of the imminent news and the multiple opportunities. I don’t think I have come across a company with so many patents pending (over 1000) and understanding the value of these in therapeutic medicines, this company has the potential for substantial growth! Will that RNS come today? Who knows but when it does, I expect fireworks!
Cheers Rich

Great post Yourshirepragma. If only more people understood valuations of the stocks they invested in as apposed to picking an incline of a number out of a hat. Of course for AIM list companies normal rules do not really apply. However, going forward companies like Avacta and the other one I am currently in are unlikely to be AIM companies very long. Then and only then will they start to realise real value. By then they will have products, patents and real value options. Finding Tham in the pence and low pounds is the best option. The other big Covid option at the moment (NCYT) would have a much stronger valuation if it were not Aim listed, given its current revenue opportunities.
So we look forward to that.

No-one here looking at the rumoured joint venture with ODX? Might see an RNS from both companies in the morning. Short and sweet??

Have a great evening!

Cheers, Rich

Latest interview with the CEO: https://youtu.be/DGHdLbuWdkc

Investors should watch this!

Corrected! Sorry for poor grammar!

For strong valuations, you need not only substantial profits, you need strong dividends and 5% yield per year would be the start. So maybe in 5 years time, if 4D are not bought out they may become a FTSE 100 company. But we have some distance to go. Let’s get off AIM first so serious investors can get on board. I am not saying PI’s are not serious, however £50k to £200k is not big. Bring in players with £10-£20 million to invest then you see big valuations.
This company has the ingredients and the motivation as well as some very clever bio technical scientists as well as a very strong team in place.
Let’s see were we go!
Cheers Rich

PS - Kind words Doggy100! Yes I have had some very good success was fortunate to find Avacta at 38p (still invested), Novacyt at 110p (minor holding today), Boohoo at 25p (not now invested), BluePrisim from 120 (not now invested) G4M from 80p, KWS from 180p (not now invested - but should have stayed with it), Bushveld at 5p (nice holding), SMT at 120p (very nice holding) and a core in Fundsmith (a suitable bank for profits - favoured by many a pension fund) which grows at average of 20% per annum. Finding great companies with huge potential after solid research is the way, not following everyone else, but sharing!

For strong valuations, you need not a not substantial profits, you need strong dividends and 5% per year would be the start. So maybe in 5 years time, if not bought out they may become a FTSE 100 company. But we have some distance to go. Let’s get of AIM first so serious investors can get on board. I am not saying PI’s are not serious. But £50k to £200k is not big. Bring in players with £10-£20 million to invest then you see big valuations.
This company has the ingredients and the motivation.
Let’s see.
Cheers Rich

Starjump, I don't think anyone can give a totally accurate valuation in the future. But, £20 billion would put 4D Pharma at 25% of GSK. I think those days are a long way off. I like to be somewhat realistic. Currently we have a market cap of £200 million, based on the potential upside from here. Let's see full validations and approvals, see the actual revenue streams and then the valuation will come by itself as the success of the 'biotherapeutics' becomes the next revolution in treatments.

I would be delighted if you end up being correct mind!

Cheers, Rich

imac1, good evening, I am sure you have been here sometime and as a new investor (3 weeks), having built a holding now well over £100k having researched this fully and know the size of the global market firstly for the IBS treatment and seeing the massive potential for asthma and Covid19 lung treatments as well as many other opportunities it is very easy to see on each project completion very good value being achieved on each level. However, I expect that we will be likely bought out within 12 to 18 months. I don't see a value of less than $1.5 billion with success on IBS, but with multiple projects completed and becoming revenue strong the value should easily be above $2 billion (assuming a US Buyer, which I think is most likely).
$2 billion is £1.55 billion so a share price of £11.41 at todays exchange rate.

So growth is strong to a minimum of £4 easily, then looking at NASDAQ and dual listing would bring huge upside and most likely additional funding. Then we could easily see strong upside in H1 2021. With potential offers from large Pharmaceutical giants in H2.

What are your thoughts as I guess you have been living a breathing 4d Pharma for some time.

Very pleased with my holding and happy to see value appreciation of the year/years ahead.

Cheers, Rich

Wiggy, I think that is highly likely!

From the ELISA test results, we know that that product using the same Affimers for detection as BAMS has the best S&S yet seen on any Covid19 test, for the original SARS-COV2 and now the latest mutation. Given what we were told yesterday the LFD which surely must be suing the same Affimers as well, which is going to be used to test if a person not only has the Virus, but most critically is contagious! That is the most important factor for the public out in the field. There are 3 symptoms which are clear to indicate the likelihood of having the virus, but if we are to stop the spread, it is vital to know if we are going to be spreading it during the infectious period. That is the purpose of our test.

Yes we need it now, but the work on it has be surely most carefully calculated to ensure we offer the most important test for infield application.

There is no sign of it going away or becoming weaker, only becoming more infectious and that is a huge concern. Nobody knows what pathway it will go or who it will effect us when the water gets much colder and we are less able to spend time outside.

On the link, you will see that the graphical chart is on that presentation as was used in the Avacta one yesterday, look at slide 22. So we can be sure Avacta are in a working partnership with Broker already.

I am not selling here, only buying, I think Avacta are set to bring the most important tests to market, which will compliment other tests already available. I also think Avacta will not have any issue selling them and they will most likely never need to use MEDUSA19! I actually think AS should walk away from that partnership as it will not be required.

I am pleased we have a US broker and I am sure that is step one in the road to a dual listing on the NASDAQ. If that happens as I have pointed out before, we will need to move onto the FTSE. Those events will be highly significant and if it is Q1 2021, that could be a perfect time. We are likely to see orders like the fantastic one announced by Novacyt today.

All investors need is patience and this will come to those who wait.

Cheers, Rich

If people are interested in investing here, spend some time learning about the company and its aims. Where?
On the company website! https://www.4dpharmaplc.com/en/newsroom/video-and-audio

Then look at where the value is. In the US a company like this with approved therapeutics would easily be valued at 3 to 4 billion US dollars. They could dual list on the US NASDAQ in the next 6 months. That will be very interesting.
Cheers Rich